NEXENTIS TECHNOLOGIES INC. Cash and Restricted Cash
NEXENTIS TECHNOLOGIES INC. (NXTS) had Cash and Restricted Cash of $7.66 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-13
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $7.66M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $4.34M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $4.01M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $6.07M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $7.66M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $4.34M 10-Q · filed 2026-05-14 | |
| 2025-12-31 | $4.01M 10-Q · filed 2026-08-13 | |
| 2025-09-30 | $6.07M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $3.16M 10-Q · filed 2026-08-13 | |
| 2025-03-31 | $2.75M 10-Q · filed 2026-05-14 | |
| 2024-12-31 | $2.21M 10-Q · filed 2026-08-13 | |
| 2024-09-30 | $2.77M 10-Q · filed 2025-11-13 | $2.77M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $4.49M 10-Q · filed 2025-08-14 | $4.49M 10-Q · filed 2024-08-14 |
| 2024-03-31 | $3.51M 10-Q · filed 2025-05-15 | |
| 2023-12-31 | $4.48M 10-K · filed 2026-03-31 | $4.48M 10-Q · filed 2024-08-14 |
| 2023-09-30 | $1.98M 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $3.02M 10-Q · filed 2024-08-14 | |
| 2022-12-31 | $5.75M 10-K · filed 2025-03-31 | $5.75M 10-Q · filed 2024-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |